SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
1-Year Return
40.04%
This Quarter Return
+8.55%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$102M
AUM Growth
-$1.25M
(-1.2%)
Cap. Flow
-$3.93M
Cap. Flow
% of AUM
-3.88%
Top 10 Holdings %
Top 10 Hldgs %
59.23%
Holding
86
New
20
Increased
24
Reduced
14
Closed
28
Top Buys
| 1 |
Verastem
VSTM
|
$3.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$2.84M |
| 3 |
Ardelyx
ARDX
|
$2.18M |
| 4 |
ITOS
iTeos Therapeutics
ITOS
|
$1.99M |
| 5 |
Nektar Therapeutics
NKTR
|
$1.3M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$7.23M |
| 2 |
UroGen Pharma
URGN
|
$3.69M |
| 3 |
Aquestive Therapeutics
AQST
|
$3.04M |
| 4 |
Establishment Labs
ESTA
|
$2.88M |
| 5 |
Galapagos
GLPG
|
$2.36M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PROF
76
Profound Medical
PROF
$133M
| – | – |
-139,942
| Closed | -$814K |
|
77
PolyPid
PYPD
$54.1M
| – | – |
-54,975
| Closed | -$149K |
|
78
RenovoRx
RNXT
$43.6M
| – | – |
-278,188
| Closed | -$275K |
|
79
scPharmaceuticals
SCPH
$300M
| – | – |
-347,687
| Closed | -$914K |
|
|
SLRN
80
DELISTED
ACELYRIN
SLRN
| – | – |
-167,580
| Closed | -$414K |
|
|
THRD
81
DELISTED
Third Harmonic Bio
THRD
| – | – |
-212,783
| Closed | -$738K |
|
|
82
UroGen Pharma
URGN
$870M
| – | – |
-333,400
| Closed | -$3.69M |
|
83
Exagen
XGN
$216M
| – | – |
-95,747
| Closed | -$344K |
|
|
SEPN
84
Septerna, Inc. Common Stock
SEPN
$630M
| – | – |
-68,084
| Closed | -$394K |
|
|
WHWK
85
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$85.3M
| – | – |
-46,698
| Closed | -$83.1K |
|
86
Iovance Biotherapeutics
IOVA
$796M
| – | – |
-20,000
| Closed | -$66.6K |
|